(Keytruda is US registered trademarks of Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., INC., USA.)
Keytruda is a prescription only drug, but not yet approved for marketing in India. However, as per the Drugs and Cosmetic Act 1940 and Rules 1945, provisions are in place for the personal import of unapproved drugs in India by a patient
Ikris Pharma Network (IPN) is a consulting pharmaceutical company which assists Patientsin preparing documentation for Name-Patient Medicine Import for their personal use. Ikris Pharma Network facilitates such access only against valid prescriptions in conformity with all local laws and regulations.
Patients/ Clinicians / Researchers can contact IPN at + 91 120 2400370 or write to at – firstname.lastname@example.org. Our manager will get in touch with you to guide you further and will assist you in doing all the paper work for securing necessary permissions from Govt.of India before Keytrudais imported directly to you.
Ikris does not manufacture, supply, re-sell or retail any drugs or medicines. All trademarks and other intellectual property in relation to drugs and medicines supplied to you by suppliers are owned by their respective manufacturers or licensees
Keytruda should be administered under the guidance of specialist doctorhaving experience in managing cancer treatments
The recommended dose is 2mg/kg body weight if it is used to treat indicated cases of melanoma. It is given by a 30-minute infusion into a vein every three weeks. Patients should always be monitored during and after the infusion for certain side effects and full blood counts should be checked before every dose of Keytruda.
Dosage are 200mg every 3 weeks if Keytruda is given to treat indicated cases of NSCLC. Same dose is recommended i.e. 200mg every 3 weeks if Keytruda is given to treat specific case of HNSCC.
If the patient develops certain seriousside effects then doctor may interrupt or stop treatment, or reduce the dose. See the summary of product characteristics on company official website for more information
It is recommended to seek your doctor’s medical advice about side effects
You can use different channel to contact Ikris Pharma Network
Tele & Mobile: You can reach us on +91 81302 90915 or +91 120 2400370 on any working days.
Email: We can also address your enquiries if sent directly to email@example.com. We will respond within 24 hours after receiving your mail. Please mention detailed enquiry, your contact number withwith ISD code while sending your mail
Website: We have very active website www.ikrispharmanetwork.comwherein you can fill enquiry form displayed on the website. We will respond within 1 working days after receiving your query form.
Office: We will be happy to address your query directly if you can plan your visit to our office during working hours. Our office address is……. (please include google map here)
New medicines which have been approved recently in USA or Europe but not yet approved in India or Rest of the world countries cannot be permitted to import or market commercially. However, they may be required for the treatment of some patients to save their lives who have exhausted all other available treatment options in their home country. Named – Patient Program is facilitate import of such medicines for personal use. There is a provision under the Indian Drugs and Cosmetics Rules, 1945, which permits needy patient to import these medicine for personal use in smaller quantities. Similar regulatory provision also exist in other countries as well.
We help such patient in preparing legal documents for import and connecting them with genuine suppliers to secure genuine products.
We will require the following documents to help in documentation for Named-Patient import